aid: cambridge-epigenetix name: Cambridge Epigenetix description: 'Cambridge Epigenetix is the Cambridge, UK genomics and epigenetics company founded on the six-base genome — resolving the four canonical DNA bases plus 5-methylcytosine and 5-hydroxymethylcytosine from a single low-input sample in one experiment — and it rebranded to biomodal in 2023. DUPLICATE RECORD: this stub was created from the secondary-market harvest backlog (Forge Global listing) under the company''s former name and profiles the same company already held in the API Evangelist network as all/biomodal, which carries the live profile (CLI command surface, domain security, blog archive, screenshots and Kin Score history). The legacy domain cambridge-epigenetix.com now 301-redirects to biomodal.com, so there is no independent Cambridge Epigenetix surface to profile. No API surface has been registered here and no artifacts have been generated, so this record does not split the company across two Kin Scores. It is queued for the duplicate-retirement procedure (survivor: biomodal).' url: https://raw.githubusercontent.com/api-evangelist/cambridge-epigenetix/refs/heads/main/apis.yml x-type: company x-source: harvest:secondary-market x-tier: duplicate x-tier-reason: duplicate-of-biomodal x-renamed-to: biomodal x-canonical-domain: https://biomodal.com x-duplicate-of: slug: biomodal survivor: true reason: biomodal is the same company under its current name and holds the live profile (CLI, domain security, blogs, screenshots, Kin Score history); all/cambridge-epigenetix is an identity-only stub harvested from a secondary-market listing under the company's former name. evidence: - source: https://cambridge-epigenetix.com/ http_status: 301 note: Legacy company domain 301-redirects to https://biomodal.com/ — the rebrand is served by the company's own DNS/edge, not inferred. - source: https://www.cambridge-epigenetix.com/ http_status: 301 note: www host redirects to https://biomodal.com/ as well. - source: https://biomodal.com/ http_status: 200 note: Live company site under the current name; already registered as the Website on all/biomodal. - source: https://app.biomodal.com/ http_status: 200 note: 'Live API host, responds text/plain "Welcome to the biomodal API"; the same host all/biomodal records. Routed to the survivor as a finding — it is currently pointed at there only as type: Login.' - source: https://software-docs.biomodal.com/en/latest/index.html http_status: 200 note: Software documentation (Sphinx) for the biomodal CLI and duet pipeline — the developer surface captured on all/biomodal. determined: '2026-08-09' procedure: duplicate-provider-retirement (retired.yml redirects; port only unique work to the survivor) specificationVersion: '0.23' created: '2026-08-09' modified: '2026-08-09' tags: - Company - Life Sciences - Genomics - Epigenetics - Multiomics - DNA Sequencing - Duplicate apis: [] maintainers: - FN: Kin Lane email: kin@apievangelist.com - FN: APIs.json email: info@apis.io common: - type: Website url: https://biomodal.com - type: SecondaryMarket url: https://forgeglobal.com/cambridge-epigenetix_stock/ x-enrichment: date: '2026-08-09' status: nochange artifacts_added: 0 pass: local-v1 note: Enrichment intentionally withheld — contract discovery resolved this stub to an existing network provider (biomodal, the company's current name). Building artifacts here would create a second scored profile for one company. Findings routed to the survivor. x-coverage: state: none reason: defunct detail: Cambridge Epigenetix rebranded to biomodal in 2023 and cambridge-epigenetix.com now 301-redirects to biomodal.com, so no surface remains under this name — the company's live developer surface is profiled in the network as all/biomodal. evidence: - url: https://cambridge-epigenetix.com/ status: 301 - url: https://biomodal.com/ status: 200 - url: https://forgeglobal.com/cambridge-epigenetix_stock/ status: 403 checked: '2026-08-09'